登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 近日，科兴生物制药股份有限公司（以下简称"公司"）全资子公司深圳科兴药业有限公司（以下简 称"深圳科兴"）收到国家药品监督管理局（以下简称"国家药监局"）签发的《药物临床试验批准通知 书》，国家药监局批准同意深圳科兴自主研发的靶向BDCA2（血树突状细胞抗原2）的创新药物"GB19 注射液"开展临床试验。 现将相关情况公告如下： 一、《药物临床试验批准通知书》基本情况 二、药品相关介绍 GB19注射液项目靶向浆细胞样树突状细胞（pDC）表面特异性表达的BDCA2靶点，其作用机制与现有 靶向B细胞通路的临床药物存在显著差异；GB19通过与BDCA2特异性结合，可抑制pDC细胞产生I型干 扰素，从而干预先天性免疫与适应性免疫间的异常活化环路。GB19注射液临床前研究展现出良好的体 外活性、免疫原性，生物利用度高，对靶点抑制时间维持超90天，安全性表现优异，如研发成功有望为 多种干扰素通路异常相关的SLE等自身免疫性疾病患者提供新的 ...

一、药品基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，三生国健药业（上海）股份有限公司（以下简称"公司"）收到国家药品监督管理局核准签发的 《受理通知书》，公司产品重组抗IL-4Rα人源化单克隆抗体注射液（研发代码：SSGJ-611）的新药上市 申请（NDA）获得受理。 由于药品在获得上市申请受理后，尚需通过国家药品监督管理局相关审评程序并获批准后方可上市、销 售。本次新药上市申请能否获得批准存在不确定性。敬请广大投资者谨慎决策，注意防范投资风险。 现将相关情况公告如下： 三、风险提示 根据我国药品注册相关的法律法规要求，药品在获得上市申请受理后，尚需通过国家药品监督管理局相 关审评程序并获批准后方可上市、销售。本次新药上市申请能否获得批准存在不确定性。 由于医药产品具有高科技、高风险、高附加值的特点，药品从临床试验报批到投产周期长、环节多，容 易受到一些不确定性因素的影响，公司将按有关规定积极推进上述研发项目，并严格按照有关规定及时 对项 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301207 证券简称：华兰疫苗 公告编号：2026-003 华兰生物疫苗股份有限公司 关于公司募集资金专项账户部分资金被冻结及解除冻结的公告 2026年2月25日 ■ 二、专项账户被冻结及解除冻结的原因 经公司自查了解，本次募集资金专项账户部分资金被冻结系公司采购合同纠纷导致，涉及金额约140万 元，经公司与河南省新乡市中级人民法院沟通，截至本公告披露日，上述资金已全部解除冻结。 三、专项账户被冻结对公司的影响 上述专项账户被冻结资金1,409,065.28元，占公司最近一期经审计净资产的0.02%，涉及金额小，冻结时 间短，且冻结期间对公司募集资金存放使用、正常经营活动未产生不利影响，募集资金投资项目均正常 实施，公司经营管理工作正常运行。 特此公告。 华兰生物疫苗股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 华兰生物疫苗股份有限公司（以下简称"公司"）于近日收到招商银行股份有限公司郑州分行营业部通 知，公司在该银行的募集资金专项账户存在部分资金被冻结及解除冻结的情况，现将有 ...

[編纂]項下的[編纂]數目 : [編纂]股H股(視乎[編纂]行使 据港交所2月25日披露，天辰生物医药(苏州)股份有限公司(简称：天辰生物医药)向港交所主板递交上市 申请，国金证券(香港)为独家保荐人。该公司曾于2025年8月21日递表港交所。招股书显示，天辰生物 医药是一家临床阶段生物制药公司，主要专注于针对过敏性及自身免疫性疾病的生物药物的自主发现与 开发。公司拥有(i)一款核心产品LP-003，一种抗IgE抗体，主要作用是阻断血液及组织中的游离IgE，从 而抑制发生IgE介导的过敏反应,旨在用于治疗过敏性疾病,包括季节性过敏性鼻炎(AR)、慢性自发性 导麻疹(CSU)、过敏性哮喘及其他过敏性疾病；及(ii)一款主要产品。 Longbio Pharma (Suzhou) Co., Ltd. 天辰生物醫藥(蘇州)股份有限公司 (於中華人民共和國註冊成立的股份有限公司) [編纂] 與否而定) 獨家保薦人 ·[編纂] 金譜券(酉澄)有限公司 OLINK SECURITIES (HK) CO. LTD. [編纂]數目 「編纂]股H股(可予[編纂]) . . [編纂]數目 「編纂]股H股(可予重新分配及視乎 「編纂 ...

智通财经APP获悉，据港交所2月25日披露，天辰生物医药(苏州)股份有限公司(简称：天辰生物医药)向 港交所主板递交上市申请，国金证券(香港)为独家保荐人。该公司曾于2025年8月21日递表港交所。 招 股书显示，天辰生物医药是一家临床阶段生物制药公司，主要专注于针对过敏性及自身免疫性疾病的 生物药物的自主发现与开发。公司拥有(i)一款核心产品LP-003，一种抗IgE抗体，主要作用是阻断血液 及组织中的游离IeE，从而抑制发生IgE介导的过敏反应，旨在用于治疗过敏性疾病，包括季节性过敏性 鼻炎(AR)、慢性自发性荨麻疹(CSU)、过敏性哮喘及其他过敏性疾病；及(ii)一款主要产品。 Longbio Pharma (Suzhou) Co., Ltd. 天辰生物醫藥(蘇州)股份有限公司 (於中華人民共和國註冊成立的股份有限公司) [編纂] [編纂]項下的[編纂]數目 : [編纂]股H股(視乎[編纂]行使 與否而定) 「編纂」行使與否而定） 獨家保薦人 ·[編纂] 金譜券(酉澄)有限公司 OLINK SECURITIES (HK) CO. LTD. [編纂]數目 「編纂]股H股(可予[編纂]) . 「編纂]數目 ...

Arcutis Biotherapeutics (NasdaqGS:ARQT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBrian Schoelpkopf - VP of Investor RelationsDouglas Tsao - Managing DirectorFrank Watanabe - President and CEOIkenna Okafor - Biotechnology Equity ResearchLata Vyravan - CFOPatrick Burnett - CMORitch Law - VP in Global Investment ResearchSeamus Fernandez - Senior Managing DirectorSerge Belanger - Managing DirectorTodd Edwards - CCOConference Call ParticipantsJudah Frommer - Executive Director, Sen ...

ADMA Biologics (NasdaqGM:ADMA) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAdam Grossman - President and CEOAnthony Petrone - MD and Equity ResearchBrad Tade - CFO and TreasurerKaitlin Kestenbaum - COO and SVP ComplianceRick Miller - MDTerry-Ann Kohler - CFO and TreasurerNone - Company RepresentativeOperatorGood afternoon. Welcome to the ADMA Biologics full year 2025 financial results and business update conference call on Wednesday, February 25, 2026. At this time, all participa ...

ADMA Biologics (NasdaqGM:ADMA) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAdam Grossman - President and CEOAnthony Petrone - MD and Equity ResearchBrad Tade - CFO and TreasurerKaitlin Kestenbaum - COO and SVP ComplianceRick Miller - MDTerry-Ann Kohler - CFO and TreasurerNone - Company RepresentativeOperatorGood afternoon. Welcome to the ADMA Biologics full year 2025 financial results and business update conference call on Wednesday, February 25, 2026. At this time, all participa ...

Arcus Biosciences (NYSE:RCUS) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBob Goeltz - CFOHolli Kolkey - VP of Corporate AffairsJen Scott - Executive DirectorJonathan Miller - Managing DirectorJuan Jaen - President and Co-FounderLi Watsek - DirectorRichard Marcus - CMOSalim Syed - Managing DirectorTerry Rosen - CEOYigal Nochomovitz - Director, Biotech Equity ResearchConference Call ParticipantsEmily Bodnar - Biotech Equity Research AnalystNone - AnalystNone - AnalystNone - Analys ...

Financial Data and Key Metrics Changes - The company reported GAAP revenue of $33 million for Q4 2025, an increase from $26 million in Q3 2025, primarily driven by collaboration with Gilead [34] - Cash at the end of Q4 was $1 billion, up from $841 million at the end of Q3, bolstered by a $288 million financing in November [34] - R&D expenses decreased to $121 million in Q4 from $141 million in Q3, while G&A expenses slightly decreased from $27 million to $26 million [34] Business Line Data and Key Metrics Changes - The confirmed overall response rate (ORR) for the 100 mg cohort of casdatifan increased from 35% to 45%, which is twice that observed with belzutifan [15] - The median progression-free survival (PFS) for the 100 mg cohort was reported at 15.1 months, significantly longer than the 5.6 months observed for belzutifan [16][17] Market Data and Key Metrics Changes - The renal cell carcinoma (RCC) market is projected to grow from over $10 billion annually today to $13 billion by 2030, with casdatifan targeting a peak sales opportunity of $5 billion in first and second-line RCC alone [22][25] - The company aims to capture a substantial share of the IO-experienced setting, which includes approximately 21,000 patients in major markets, nearly double the third-line patient population where belzutifan is currently approved [25] Company Strategy and Development Direction - The company is focused on establishing casdatifan as the best-in-class HIF-2 inhibitor and the new standard of care for clear cell renal cell carcinoma [4] - A fast-to-market strategy is being employed with the PEAK-1 study, which is actively enrolling and designed to establish CAS plus cabozantinib as the new standard of care in IO-experienced clear cell RCC [18] - The company is also developing a TKI-free regimen for frontline therapy, which is expected to improve patient quality of life and treatment outcomes [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized that 2026 will be a transformative year for the company, with significant data presentations and advancements in the clinical program for casdatifan [4] - The management expressed confidence in the differentiation of casdatifan compared to belzutifan, particularly regarding safety and efficacy profiles [6][10] Other Important Information - The company plans to initiate a phase 3 study for casdatifan in the frontline setting by the end of 2026, contingent on safety and efficacy data [20] - The immunology portfolio is also being developed, with two programs expected to enter the clinic over the next 12 months [28] Q&A Session Summary Question: What trials are being looked at for IO benchmarks as the company moves away from TKI-based regimens? - Management indicated that ipilimumab-nivolumab (ipi-nivo) is a key focus, with a primary progression rate of 20%-25% and a PFS of around 12 months serving as benchmarks for improvement [42][43] Question: What is the status of the volrustomig plus casdatifan study? - The study was paused but continues to provide valuable data, with no primary progression observed since dose adjustments [49][50] Question: How do deeper EPO reductions correlate with responses in biomarker analyses? - There is a soft correlation between higher baseline EPO levels and the extent of reduction, indicating stronger HIF-2 activity in tumors [54][56] Question: What are the expectations for the LITESPARK-011 study? - Management expects good data from Merck's study, which will validate the field and potentially drive enrollment for the PEAK-1 study [64][65]